An emergence of adenocarcinoma in the lung following longstanding systemic sclerosis: a case report
Main Article Content
Abstract
Abstract: Systemic sclerosis (SSc) is one of the chronic autoimmune diseases characterized by the infiltration of the excess collagen in various organs especially the skin. It is found associated with more prevalence of internal malignancies particularly the lung carcinoma. Herein we reported a case of adenocarcinoma confining within the lung in a Thai patient who had long-standing SSc. He was a 67-year-old Thai patient presenting with fever and productive cough for two weeks. He had been clinically diagnosed as having SSc based on the evidence of the sclerodactyly, the telangiectasia at the upper chest wall, multiple pitting scars at many finger tips and the interstitial lung disease and he had been treated with colchicine and azathioprine for 10 years. Besides the sclerodactyly and the telangiectasia, the lymphadenopathy and lung abnormality were not detected on the physical examination. The chest film and the computed tomography of the lung revealed a 2x2.8 cm mass at the left lower lung field. The pathology of the lung mass biopsied via the bronchoscopy was adenocarcinoma. LDH was 1,814 U/L. HIV antigen/antibody was negative. He was definitely diagnosed as having adenocarcinoma of the lung with an underlying long term SSc although he was not a smoker. He did not accept the further investigations and/or any treatment. Our case seemed to support the fact that the prevalence of cancers particularly the adenocarcinoma of the lung was significantly increased among SSc patients more than that of general population.
Article Details
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Balbir-Gurman A, Braun-Moscovici Y. Scleroderma - new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol 2012; 26: 13-24.
Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 Classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Arthritis Rheum 2013; 65: 2737-47.
Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum 2013; 65: 1913-21.
Panicheewa S, Chitrabamrung S, Verasertniyom O, Vanichaphantu M, Kraisit SO, Chiewsilp P. Diffuse systemic sclerosis and related diseases in Thailand. Clin Rheumatol 1991; 10: 124-9.
Ruangjutipopan S, Kasitanon N, Louthrenoo W, Sukitawut W, Wichainun R. Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis. J Med Assoc Thai 2002; 85: 1204-9.
Downey P, Cummins R, Moran M, Gulmann C. If it's not CK5/6 positive, TTF-1 negative it's not a squamous cell carcinoma of lung. APMIS 2008; 116: 526-9.
Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011; 24: 1348-59. doi: 10.1038/modpathol.2011.92.
Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 ex-pression in pulmonary adenocarcinomas. Am J Surg Pathol 2002; 26: 767-73.
Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003; 62: 728-31.
Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento E, La Vecchia C, et al. Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational study. Rheumatol (Oxford) 2012; 52: 143-54.
Varga J. Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults. In: Up-ToDate, Basow DS (Ed), UpToDate, Waltham MA, 2008.
Katzen JB, Raparia K, Agrawal R, Patel JD, Rademaker A, Varga J, et al. Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: A cross sectional study. PLoS One 2015; 10: e0117829. doi: 10.1371/journal.pone.0117829.
Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: A population-based cohort study. Arthritis Rheum 2005; 52: 2415-24.
Shah AA, Rosen A, Hummers L, Wigley F, Casci-ola-Rosen L. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010; 62: 2787-95.
Zeineddine N, El Khoury L, Mosaka J. Systemic sclerosis and malignancy: A review of current data. J Clin Med Res 2016; 8: 625-32. doi: 10.14740/jocmr2606w
Schwaiblmair M, Behr W, Haeckel T, Mark B, Foerg W, Berghaus T. Drug induced interstitial lung disease. Open Respir Med J 2012; 6: 63-74.
Archontogeorgis K, Steiropoulos P, Tzouvelekis A, Nena E, Bouros D. Lung cancer and interstitial lung disease: A systemic review. Pulmonary Med 2012 (2012), Article ID 315918, 11 pages. http://dx.doi.org/10.1155/2012/ 315918.